Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Pain
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Single Group AssignmentMasking: Triple (Participant, Care Provider, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
This aim proposes that guanfacine would be a useful drug to deter Opioid-Induced Hyperalgesia (OIH) when combined with an opioid (morphine) in chronic pain management.
This aim proposes that guanfacine would be a useful drug to deter Opioid-Induced Hyperalgesia (OIH) when combined with an opioid (morphine) in chronic pain management.
Tracking Information
- NCT #
- NCT01681264
- Collaborators
- National Institutes of Health (NIH)
- National Institute on Drug Abuse (NIDA)
- Investigators
- Principal Investigator: Jianren Mao, M.D., Ph.D. Massachusetts General Hospital
Get Well Soon